iXCells Biotechnologies is a supplier for a variety of iPSC and iPSC-derived cells, human & animal primary cells as well as media and cell culture reagents and tools such as growth factors and cytokines. They also offer services for custom cell isolation (primary cells and immune cells), as well as IPS Cell Generation and IPSC differentiation. Furthermore, they also have cell-based and immune assays in their portfolio.
Overview of our products for iXCells Biotechnologies.
Keine Elemente gefunden
Cells for drug discovery solutions through disease-relevant cell models.
Choose from human and animal primary cells from healthy and diseased tissues to enhance their portfolio of iPSCs and their variants.
Donors from skin, liver, and kidney.
Regular cells and cells important for disease models with a focus on neurobiology, primary cell collections from skin, liver and kidney from matching donors and over 150 unique donors of PBMCs and immune cells.
Cells focused on neurobiology.
iPSC & iPSC-derived cells.
A collection of iPS cell products and their variants that includes both normal cells and cells relevant to disease models, focused on neurobiology.
iXCells Biotechnologies was the first one providing iPSC-derived motor neurons and has subsequently expanded its catalog with neural stem cells (NSCs), CNS and peripheral neurons, skeletal muscle and supporting cells. Our patient-derived iPSC collection includes cells for ALS, Alzheimer's disease, diabetes, metabolic diseases and Parkinson's disease, which add to our portfolio from healthy donors.
Human and Animal Primary Cells
iXCells offers a wide portfolio of human and animal primary cell offerings and the ability to perform custom isolations upon demand. Normal and disease model relevant cells with a strong focus in neurobiology, matched donor primary cell collections from skin, liver and kidney and over 150 unique donors of PBMCs and immune cells.
A diverse collection of animal primary cell offerings and the ability to perform custom isolations upon demand. All cell materials generated come with an in-house generated CoA and product information sheet to ensure our customers have all relevant information necessary to advance their research. Ask Peter for your special requests.
Facts and References about iXCells.
iXCells was founded in 2014 and is based in San Diego, CA, USA. The cell biology and cell technology company is dedicated to offer innovative pre-clinical drug discovery solutions with the focus on disease relevant cellular models. They have over 75 primary cell offerings and the ability to perform custom isolations upon demand.
References for Human PBMCs
Lu, M. J., & Lu, Y. (2022). 5-hydroxymethylcytosine (5hmc) at or near cancer mutation hot spots as potential targets for early cancer detection. BMC Research Notes, 15(1). https://doi.org/10.1186/s13104-022-06028-w -- Learn More
Cui, X., Ma, C., Vasudevaraja, V., Serrano, J., Tong, J., Peng, Y., . . . Chen, W. (2020). Dissecting the immunosuppressive tumor microenvironments in glioblastoma-on-a-chip for optimized pd-1 immunotherapy. ELife, 9. doi:10.7554/elife.52253 -- Learn More
Demaree, B., Delley, C. L., Vasudevan, H. N., Peretz, C. A., Ruff, D., Smith, C. C., & Abate, A. R. (2020). Joint profiling of dna and proteins in single cells to dissect genotype-phenotype associations in leukemia. BioRxiv. doi:10.1101/2020.02.26.967133 -- Learn More
Marrero, I., Maricic, I., Morgan, T. R., Stolz, A. A., Schnabl, B., Liu, Z., . . . Kumar, V. (2020). Differential activation of unconventional T cells, including Inkt cells, In Alcohol‐Related liver disease. Alcoholism: Clinical and Experimental Research, 44(5), 1061-1074. doi:10.1111/acer.14323 -- Learn More
Puniya, B. L., Amin, R., Lichter, B., Moore, R., Ciurej, A., Townsend, S., . . . Helikar, T. (2020). Integrative computational approach identifies new targets in cd4+ t cell-mediated immune disorders. doi:10.1101/2020.01.02.893164 - Learn More
Sheng, H., Marrero, I., Maricic, I., Fanchiang, S. S., Zhang, S., Sant'Angelo, D. B., & Kumar, V. (2019). Distinct plzf+cd8αα+ unconventional t cells enriched in liver use a cytotoxic mechanism to limit autoimmunity. The Journal of Immunology, 203(8), 2150-2162. doi:10.4049/jimmunol.1900832 -- Learn More
Maricic, I., Marrero, I., Eguchi, A., Nakamura, R., Johnson, C. D., Dasgupta, S., . . . Kumar, V. (2018). Differential activation of hepatic invariant nkt cell subsets plays a key role in progression of nonalcoholic steatohepatitis. The Journal of Immunology, 201(10), 3017-3035. doi:10.4049/jimmunol.1800614 -- Learn More
Cerignoli, F., Abassi, Y. A., Lamarche, B. J., Guenther, G., Santa Ana, D., Guimet, D., . . . Xi, B. (2018). In vitro immunotherapy potency assays using real-time cell analysis. PLOS ONE, 13(3). doi:10.1371/journal.pone.0193498 - Learn More
Pryke, K. M., Abraham, J., Sali, T. M., Gall, B. J., Archer, I., Liu, A., . . . DeFilippis, V. R. (2017). A novel agonist of the trif pathway induces a cellular state refractory to replication of zika, chikungunya, and dengue viruses. MBio, 8(3). doi:10.1128/mbio.00452-17 -- Learn More
Nomanbhoy, T. K. (2017). CHEMOPROTEOMIC evaluation of target engagement in clinical samples. Cancer Chemistry. doi:10.1158/1538-7445.am2017-225 -- Learn More
We are here for you.
Call us, write to us or make an appointment for a personal conversation
with us on site. Please do not hesitate to call, we love to be at
your service anytime.
PELOBIOTECH GmbH
Behringstrasse 10
82152 Germany
Phone +49 (0) 89 517 286 59 0
Mail info@pelobiotech.com
